Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alloantigen-Specific Tregs in Liver Transplantation
NCT03577431Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2019
- Primary completion
- Feb 2026
- Modality
- Regulatory T Cells (Tregs), Adoptive Cell Transfer
- Countries
- 1
01
Overview
A Phase 2 trial of arTreg-CSB in liver transplant, sponsored by National Institute of Allergy and Infectious Diseases. Started Mar 2019; status: completed.
02
Drugs
arTreg-CSB
03
Conditions
liver transplant
Beyond the preview
Go deeper on NCT03577431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03577431.